<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1478">
  <stage>Registered</stage>
  <submitdate>20/07/2006</submitdate>
  <approvaldate>21/07/2006</approvaldate>
  <actrnumber>ACTRN12606000315516</actrnumber>
  <trial_identification>
    <studytitle>The Quality of Life Outcomes and the Pharmacokinetic and Pharmacodynamic Sequelae of Testosterone Undecanoate Injections compared with Testosterone Implants for Androgen Replacement Therapy in men with Classical Male Hypogonadism</studytitle>
    <scientifictitle>The Quality of Life Outcomes and the Pharmacokinetic and Pharmacodynamic Sequelae of Testosterone Undecanoate Injections compared with Testosterone Implants for Androgen Replacement Therapy in men with Classical Male Hypogonadism</scientifictitle>
    <utrn />
    <trialacronym>TU/TU study</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Male hypogonadism</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic and endocrine disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>40 men with classical androgen deficiency will trial both testosterone undecanoate 1000mg injections and 4 x 200mg Testosterone Implant pellets in a randomised sequence over a period of approximately one year</interventions>
    <comparator>No comparator.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Individual and disease specific quality of life variables (reproductive hormones, subjective symptoms of androgen deficiency).</outcome>
      <timepoint>These will be measured at baseline, +2weeks, +4 weeks, +6 weeks, +12 weeks, +18 weeks and +30 weeks for the TU arm of the study and baseline, +2 weeks, +4 weeks, +12 weeks and at approximately 20 weeks for the TI arm of the study.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Androgen sensitive clinical measures (body composition, muscle strength, hemoglobin, sexual activity). </outcome>
      <timepoint>These will be measured at baseline, + 12 weeks and at + 30 weeks for the TU arm and approximately 20 weeks for the TI arm.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> Established androgen deficiency requiring testosterone replacement therapy.  Otherwise medically stable.  Able to understand and comply with the study design.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known contraindications to androgen therapy (eg. prostate cancer).  Known allergy to castor oil vehicle of injections.  Known significant systemic or mental illness.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>double envelopes created by someone not directly involved in recruitment</concealment>
    <sequence>random number generator on computer</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>17/07/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Schering Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Schering Pty Ltd</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is designed to determine whether men with androgen deficiency prefer a long acting injection that requires administration each three months or whether they prefer subcutaneously implanted testosterone pellets administered approximately each 6 months.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Concord Repatriation General Hospital Human Research Ethics committee</ethicname>
      <ethicaddress>Department of Clinical Andrology Building 22 CRGH Hospital Rd Concord 2139</ethicaddress>
      <ethicapprovaldate>19/04/2006</ethicapprovaldate>
      <hrec>CH62/6/2006-016</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ass Prof Ann Conway</name>
      <address>Department of Clinical Andrology
Building 22
CRGH
Hospital Rd.
Concord NSW 2139</address>
      <phone>02 9767 7222</phone>
      <fax>02 9767 7221</fax>
      <email>sharynk@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof D J Handelsman</name>
      <address>ANZAC Research Institute
CRGH 
Hospital Rd 
Concord NSW</address>
      <phone>02 9767 7100</phone>
      <fax>02 9767 7221</fax>
      <email>djh@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>